Efficacy and Safety of mizoribine for MPO-ANCA associated vasculitis; A multicenter randomized controlled trial (Mizoribin for ANCA RPGN Relapse-Prevention study:MARPGN study)

Efficacy and Safety of mizoribine for MPO-ANCA associated vasculitis; A multicenter randomized controlled trial (Mizoribin for ANCA RPGN Relapse-Prevention study:MARPGN study) - MARPGN study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000708

Enrollment

126

Registered

2007-05-06

Start date

2007-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MPO-ANCA associated vasculitis

Interventions

treatment with mizoribine according to the GFR once a day no treatment with mizoribine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in remmision state of ANCA-associated vasculitis

Exclusion criteria

Exclusion criteria: Patients with allergy with Mizoribine Patients with leucocytosis(<3000/mm3) Patients treated with other immunosuppression drug within four weeks

Design outcomes

Primary

Measure	Time frame
BVAS score, time from remmision to relapse, relapse rate	—

Secondary

Measure	Time frame
MPO-ANCA titer, CRP, GFR, amount dose of corticosteroid through the study	—

Countries

Japan

Contacts

Public ContactKunihiro Yamagata

Division of Clinical Sciences, Faculty of Medicine, University of Tsukuba Department of Nephrology

kidney@md.tsukuba.ac.jp029-853-3202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026